spacer
home > ebr > spring 2002 > harnessing the immune system against cancer
PUBLICATIONS
European Biopharmaceutical Review

Harnessing the Immune System Against Cancer

Cancerous cells contain numerous mutations, qualitative and quantitative, spatial and temporal, relative to their normal, non-cancerous counterparts. At certain periods during tumour cells' growth and spread, a proportion of these are capable of being recognised by the hosts' immune system as abnormal. This has led to numerous research efforts worldwide to develop immunotherapies that harness the power of the hosts' immune system and direct it to attack the cancerous cells, thereby eliminating such aberrant cells at least to a level that is not life-threatening (1,2). The market has recognised the potential of this approach, and the cancer vaccine revenues alone are forecast at US$3 billion by 2008 (3). Numerous approaches have been taken in the quest for cancer immunotherapies, which can be classified under the five categories covered in this article:


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Anthony Walker, CEO of Onyvax Ltd

Prior to co-founding Onyvax in 1997, Anthony Walker spent 10 years as a Management Consultant, specialising in the pharmaceutical and biotechnology industries. During his eight years at Arthur D. Little, Anthony was appointed a European Director, responsible for the London-based pharmaceutical practice that he founded, and at The Wilkerson Group (London) he had responsibility for the UK, Benelux and Scandinavian markets.
Anthony has consulted to 12 of the top 25 Rx companies and has also worked closely with over 20 biotechnology companies. In addition, he has produced expert reports for a number of UK biotech IPOs.

spacer
Dr Anthony Walker
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Optimizing pharmaceutical processes

An increase in requirements from regulatory agencies around the world, combined with a growing demand for drugs in prefilled injections systems a trend that industry experts have projected will continue has led pharmaceutical and biotech supply chains to gain in significance. Well established and optimized processes are crucial for offering uninterrupted market supply. To satisfy its customers a CDMO must foster flexibility, efficiency and safety throughout the entire supply chain. The most important goal for all parties involved in the bio-pharma business is maximization of product quality where even small decisions can make a big difference. Future-oriented pharma processes can add value to any compound.
More info >>

White Papers

Overcoming research challenges with Adaptive Trials

PCI Pharma Services

There has been cause for concern within the pharmaceutical industry over the last five years, regarding increasing research and development costs, combined with a fall in the number of new drugs brought to market. In an attempt to overcome this issue there has been a significant rise in the use of adaptive clinical trial designs, whilst saving time and money as well as facilitating more effective decision making. One of the biggest challenges that pharmaceutical companies have experienced has been delivering compliant clinical trials supplies across diverse patient populations in the relatively short timeframes that adaptive trial designs require, remaining focused on ensuring that patient compliance and product quality is in no way compromised. This demand has led to the launch of fast response services that support Research and Development in responding to changing dosing regimens mid-trial.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement